Shenzhen-Based Pregbio Raises Funds for Non-Invasive Prenatal Gene Detection
Pregbio, a Shenzhen-based non-invasive prenatal gene detection company, has reportedly raised an undisclosed amount of...
February 2022
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it...